Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Scientists have discovered a protein which could improve the success rate of one of the most common drugs used to fight ovarian cancer, according to a new study.
Researchers funded by Cancer Research UK and the Medical Research Council found that the loss of a protein called TGFBI caused paclitaxel to fail.
The drug is a common chemotherapy treatment for ovarian cancer but only half of patients with the disease respond well to the therapy.
Experts based at the Cambridge Research Institute at Cambridge University looked at ovarian cancer cell lines and data from 20 patients in a prospective trial.
Those who showed no response to the drug had less TGFBI in their pre-treatment samples, compared with those whose condition improved.
Post-treatment studies showed that the death of cancer cells happened when there were high levels of the protein.
The study of 20 patients at Addenbrooke's Hospital suggests that patients who lack the protein could be spared chemotherapy that will not benefit them.
Dr James Brenton, lead researcher and clinician, said: "TGFBI is lost in one third of primary ovarian cancers and it is possible that this protein could be used as a biomarker for selecting patients likely to respond to this class of drug.
"Our findings offer hope not only for improved ovarian cancer treatment, it may also lead to improvements in the success rate of other taxane drugs used to treat lung and breast cancer."
Prof Herbie Newell, Cancer Research UK's director of translational research, said: "We are entering a period of cancer treatment where more drugs are targeted at those people who will benefit the most.
"This personalised medicine approach potentially means treatments will be more effective with fewer side effects.
"This is really important for diseases like ovarian cancer that can be challenging to treat."
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments